Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 57 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Immunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes

  • Jing Dong1
  • Ye Jin2
  • Yaning Li3
  • Zhi Zhang1
  • Xuemei Zhang4
4 affiliations
  1. 1Department of Oncology, Tangshan Gongren Hospital
  2. 2College of Clinical Medicine, North China University of Science and Technology
  3. 3Graduate School, Hebei Medical University
  4. 4College of Life Science, North China University of Science and Technology
Open at sourceDOICite

Abstract

Background: Immune checkpoint inhibitors (ICIs) have become an important component of systemic therapy for esophageal cancer, but real-world safety data for combining ICIs with taxane- and platinum-based chemotherapy remain limited. This study compared adverse-event (AE) profiles, time to onset (TTO), and reported mortality between ICI-based combination therapy and ICI monotherapy in esophageal cancer.

Methods: Using the FDA adverse event reporting system (FAERS), we screened reports from Q3/2019 through Q1/2026 for esophageal cancer involving pembrolizumab or nivolumab as the primary suspect. Combination included immunotherapy with a taxane and platinum; monotherapy included immunotherapy alone. Disproportionality was assessed via reporting odds ratios ( RORs ) and proportional reporting ratios ( PRRs ). TTO was evaluated using Kaplan-Meier and Cox models , and logistic regression examined factors for reported mortality.

Results: Among 1,580 eligible reports (103 combination, 1,477 monotherapy), distinct AE signal profiles emerged. In combination, prominent signals were gastrointestinal, hematologic, and respiratory, with esophagitis showing the strongest signal ( ROR , 61.97; 95%CI , 22.80–168.48), followed by decreased lymphocyte count ( ROR , 59.68; 95%CI , 28.99–122.83) and behaviour disorder ( ROR , 42.85; 95%CI , 13.58–135.17). In monotherapy, signals were more immune-mediated, including immune-mediated cystitis ( ROR , 261.05; 95%CI , 113.92–598.18), immune-mediated cholangitis ( ROR , 87.65; 95%CI , 41.36–185.78), immune-mediated endocrinopathy ( ROR , 85.51; 95%CI , 27.19–268.89) and so on. Among 571 reports with TTO data, AEs occurred significantly earlier in combination than monotherapy, with median TTOs of 23 days ( IQR , 8-72) vs. 49 days ( IQR , 21–129) ( log-rank P < 0.001), consistent across age, sex, weight, and reporting-year subgroups. Reported mortality was 6.8% for combination vs. 21.1% for monotherapy. After multivariable adjustment, combination was associated with lower reported mortality odds than monotherapy ( adjusted OR , 0.27; 95%CI , 0.06–0.77; P = 0.033).

Conclusion: ICI-based combination therapy showed a distinct AE profile and significantly earlier AE onset than monotherapy, but lower reported mortality odds. These findings underscore the need for early monitoring of hematologic, gastrointestinal, and respiratory toxicities during combination therapy.

Related

  1. Evaluation of the efficacy and safety of different cycles of neoadjuvant chemotherapy combined with immunotherapy in locally advanced esophageal squamous cell carcinoma: a multi-center, real-world study.
    Huilai Lv, Zuopeng Wang, Chunyong Su +11
    World journal of surgical oncologyPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  2. Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis
    Hai Zhang, Yujing Liang, Chaolin Li +3
    Frontiers in medicinePeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  3. Association between absolute lymphocyte count and outcomes of radiotherapy combined with immunotherapy in elderly patients with inoperable esophageal squamous cell carcinoma
    Youqin Jiang, Weiwei Chen, Daguang Ni +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJEurope PMC
  4. Immune checkpoint inhibitors (ICIs) for second-line retreatment in esophageal cancer progressing after first-line immunotherapy: a single-center retrospective cohort study
    Yixin Kang, Youjia Mi, Ce Zhang +4
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Drug–drug Interaction Signals for Sexual Dysfunction with Antidepressants and Antipsychotics: A Pharmacovigilance–pharmacodynamic Study
    Rina Horii, Masakazu Hatano, Shigeki Yamada
    Clinical Psychopharmacology and NeurosciencePeer-reviewedCC BY-NC 4.0Full textPharmacology & toxicologyPMC

Cite

BibTeXRIS
BibTeX
@article{dong2026immunotherapy,
  title = {{Immunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes}},
  author = {Jing Dong and Ye Jin and Yaning Li and Zhi Zhang and Xuemei Zhang},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = nov,
  doi = {10.3389/fphar.2026.2002339},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.2002339/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Immunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes
AU  - Jing Dong
AU  - Ye Jin
AU  - Yaning Li
AU  - Zhi Zhang
AU  - Xuemei Zhang
PY  - 2026
DA  - 2026/11/05
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.2002339
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.2002339/full
AB  - Background: Immune checkpoint inhibitors (ICIs) have become an important component of systemic therapy for esophageal cancer, but real-world safety data for combining ICIs with taxane- and platinum-based chemotherapy remain limited. This study compared adverse-event (AE) profiles, time to onset (TTO), and reported mortality between ICI-based combination therapy and ICI monotherapy in esophageal cancer.  Methods: Using the FDA adverse event reporting system (FAERS), we screened reports from Q3/2019 through Q1/2026 for esophageal cancer involving pembrolizumab or nivolumab as the primary suspect. Combination included immunotherapy with a taxane and platinum; monotherapy included immunotherapy alone. Disproportionality was assessed via reporting odds ratios ( RORs ) and proportional reporting ratios ( PRRs ). TTO was evaluated using Kaplan-Meier and Cox models , and logistic regression examined factors for reported mortality.  Results: Among 1,580 eligible reports (103 combination, 1,477 monotherapy), distinct AE signal profiles emerged. In combination, prominent signals were gastrointestinal, hematologic, and respiratory, with esophagitis showing the strongest signal ( ROR , 61.97; 95%CI , 22.80–168.48), followed by decreased lymphocyte count ( ROR , 59.68; 95%CI , 28.99–122.83) and behaviour disorder ( ROR , 42.85; 95%CI , 13.58–135.17). In monotherapy, signals were more immune-mediated, including immune-mediated cystitis ( ROR , 261.05; 95%CI , 113.92–598.18), immune-mediated cholangitis ( ROR , 87.65; 95%CI , 41.36–185.78), immune-mediated endocrinopathy ( ROR , 85.51; 95%CI , 27.19–268.89) and so on. Among 571 reports with TTO data, AEs occurred significantly earlier in combination than monotherapy, with median TTOs of 23 days ( IQR , 8-72) vs. 49 days ( IQR , 21–129) ( log-rank P < 0.001), consistent across age, sex, weight, and reporting-year subgroups. Reported mortality was 6.8% for combination vs. 21.1% for monotherapy. After multivariable adjustment, combination was associated with lower reported mortality odds than monotherapy ( adjusted OR , 0.27; 95%CI , 0.06–0.77; P = 0.033).  Conclusion: ICI-based combination therapy showed a distinct AE profile and significantly earlier AE onset than monotherapy, but lower reported mortality odds. These findings underscore the need for early monitoring of hematologic, gastrointestinal, and respiratory toxicities during combination therapy.
SN  - 1663-9812
ER  -